Find Clinical Trial

Home » Find Clinical Trials » Effects of S 18886 on platelet function in type 2 diabetic patients treated by low-dose aspirin and with elevated levels of thromboxane A2. A multicentre, randomised, double-blind, cross-over study comparing S 18886 30 mg o.d. versus aspirin 100 mg o.d. administered orally.

Effects of S 18886 on platelet function in type 2 diabetic patients treated by low-dose aspirin and with elevated levels of thromboxane A2. A multicentre, randomised, double-blind, cross-over study comparing S 18886 30 mg o.d. versus aspirin 100 mg o.d. administered orally.

← Back

Study Phase	Phase 2

Therapeutic Area	Metabolism

Indication	Diabetes - Type II

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	TERUTROBAN, S018886

Active Substance Code	S018886

Protocol Code	CL2-18886-031

EudraCT Code	2008-005262-31

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.